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institutionalized, U.S. civilian population were analyzed.
MEPS data provided information on demographics,
health conditions, prescription medications, and health
resource utilization. Persons >= 45 years with COPD
(ICD-9 = 491 [chronic bronchitis], ICD-9 = 492 [emphy-
sema]) as their primary diagnosis were included. Direct
medical costs were deﬁned as the sum of insurance and
patient payments for health services attributable to
COPD. This included emergency department visits, 
hospital outpatient visits, inpatient stays, outpatient 
clinic and ofﬁce visits, and prescription medications.
Descriptive statistics were conducted. Results were
weighted to reﬂect population estimates.
RESULTS: In 1996, 1.4 million people over 45 years of
age received medical treatment for COPD. 65.7% of this
cohort were 65 and older. Direct medical costs attribut-
able to COPD totaled $3.4 billion. COPD-associated
direct medical costs for persons 65 and older were $3.1
billion. 77% of the total medical costs in this group of
patients were due to hospital admissions, 14.3% were for
prescription medications, and 5.5% were for emergency
room and hospital outpatient visits.
CONCLUSIONS: Inpatient admissions in the elderly
accounted for the majority of the COPD-associated costs.
Interventions designed to manage COPD more effectively,
including appropriate utilization of prescription medica-
tions, may help minimize ER visits and hospital admis-
sions, thereby decreasing total costs of managing COPD.
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OBJECTIVES: Outcomes in asthmatic patients may vary
depending on the controller medication used. Observa-
tional studies of outcomes of asthma therapy are needed
to understand the implications of choice of controller 
in different populations. This study compared asthma-
related health care costs and medication compliance
between patients newly started on montelukast compared
to low-dose ﬂuticasone propionate as controller therapy
in Medicaid-enrolled asthmatic patients previously using
only short-acting beta-agonists.
METHODS: Using data from the North Carolina 
Medicaid program, we identiﬁed continuously enrolled
asthmatic patients starting either ﬂuticasone propionate
44mg (FP 44), an inhaled corticosteroid, (n = 353) or
montelukast 5 and 10mg, an oral leukotriene modiﬁer, (n
= 525) in the year 1998. Patients were followed for 1-
year pre and post controller initiation for health care
service utilization, medication reﬁll patterns, and costs. A
mixed modeling procedure with indicator variables to
adjust for potential confounders was used to determine
the adjusted cost impact of therapy initiation.
RESULTS: The average asthma-related health care costs
were $1199 ($1180 for FP, $1212 for montelukast) in
Year 1. These costs increased to $1342 ($1235 for FP,
$1415 for montelukast) in Year 2. There were no signif-
icant differences in the adjusted asthma-related health
care costs. In both groups, physician visits were signiﬁ-
cantly higher in Year 2 (50% increase for FP, 23% for
montelukast, both p < 0.01). However, even after allow-
ing for a wider compliance range for FP (50–150%) com-
pared to montelukast (80–120%), we found montelukast
users to be more compliant with therapy in Year 2 (RR:
1.97; 95% CI: 1.25, 3.13).
CONCLUSIONS: Although there were no cost or 
health care utilization differences between the two groups
in the post-controller initiation year, montelukast use was
associated with signiﬁcantly better treatment compliance
than FP use, which could have signiﬁcant implications 
for long-term patient outcomes and costs in 
Medicaid-enrolled asthmatic patients.
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OBJECTIVES: Asthma controller therapy with multiple
controller medications is increasingly common. Data is
needed regarding the implications of the choice for a
second controller medication. The goal of this study 
was to compare asthma-related health care costs and
medication compliance between patients newly started on
montelukast compared to salmeterol as additional 
controller therapy among patients already using inhaled
corticosteroids (ICS).
METHODS: Using data from the North Carolina 
Medicaid program, we identiﬁed continuously enrolled
asthmatic patients using ICS as controller therapy (≥4
reﬁlls in year before starting additional controller) initi-
ating either salmeterol a long-acting beta agonist, (n = 97)
or montelukast, an oral leukotriene modiﬁer, (n = 101) in
the year 1998. Each group was observed for 1-year pre
and post additional controller medication initiation for
health care service utilization, medication reﬁll patterns,
and costs. A mixed modeling procedure using indicator
variables was used to determine confounder controlled
cost impact of therapy initiation.
RESULTS: The average asthma-related health care costs
were $1955 ($2225 for salmeterol, $1695 for mon-
telukast) in year 1. These average costs did not signiﬁ-
cantly increase for either group ($2055 entire population,
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$2205 for salmeterol, $1911 for montelukast) in year 2.
There were no signiﬁcant differences in the adjusted
asthma-related health care costs and utilization. Although
the montelukast group showed higher compliance in the
bivariate analysis, this was not signiﬁcant in the multi-
variate regression. Overall ICS use decreased by 16% in
year 2 (p < 0.01), but there were no differences between
the two groups with regard to relative reduction of ICS
reﬁlls.
CONCLUSIONS: Adding either montelukast or salme-
terol as additional controller to ICS therapy was not 
associated with changes in either health care service 
utilization or costs in Medicaid-enrolled asthmatic
patients. However, their addition was associated with a
decrease in inhaled corticosteroid use, suggesting
decreased compliance in patients on the 2-drug regimen.
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OBJECTIVES: To estimate differences in length of stay
(LOS), emergency room (ER) visits and charges for 
inpatient asthma care between children and adults based
on insurance coverage, patient and hospital-based 
characteristics.
METHODS: The 1997 Nationwide Inpatient Sample of
the Healthcare Cost and Utilization Project data were
used to extract 183,400 childhood (age <17 years) and
251,760 adult asthma cases (primary diagnosis using
ICD-9 codes 493.00–493.91). Two-way ANOVA was
conducted to determine differences in LOS and total
charges between adult and childhood asthma based on
type of insurance coverage (Medicaid, private insur-
ance/HMO and self-pay) while chi-square analysis was
conducted to detect differences based on number of ER
visits. Regression models were developed separately for
childhood and adult asthma to examine if LOS and total
charges (multiple regression) and ER visits (logistic
regression) are affected by patient-related (race, gender,
number of co-morbidities and insurance status) and 
hospital-related (bed-size, location, teaching and 
ownership status) factors.
RESULTS: Overall, average length of stay for childhood
and adult asthma was 2.43 days and 3.98 days, respec-
tively. Mean total charges for childhood asthma was
$4,532 as compared to $7,713 for adult asthma. Almost
70% of adult asthmatics had ER visits as compared to
62% of asthmatic children. Adults had signiﬁcantly
higher total charges, LOS and ER visits for all types of
payers as compared to children. Medicaid-eligible adults
and children showed highest hospitalization charges, LOS
and ER visits. Non-whites, patients with higher number
of co-morbidities, urban and teaching hospitals were
associated with higher charges, LOS and ER visits, for
both adult and childhood asthma.
CONCLUSIONS: Adult asthmatics, especially Medicaid
beneﬁciaries, have higher inpatient charges, LOS and ER
visits as compared to asthmatic children. Future studies
should be aimed at reducing asthma-related ER visits and
investigating variations in resource utilization based 
on insurance coverage and patient and hospital-related
characteristics.
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OBJECTIVES: Comparative estimation cost and 
inﬂuence on quality of life in children with middle severe
asthma sodium cromoglycate and sodium nedocromil.
METHODS: Cost-utility analysis was conducted in
Child’s Municipal Asthma-Centre during 1998–2000
years in 100 children with asthma. We determined one
year expenses for quality adjusted life years (QALY). For
estimation quality of life we used “Childhood question-
naire” by A. West, D. French adapted for Russian by 
V. Petrov and I. Smolenov and index Rosser-Kind. 
Estimation of expenditures included direct and indirect
expenses.
RESULTS: The investigation revealed the differences in
therapeutic effectiveness and quality of life depending on
treatment method. Using therapy by nedocromil sodium
during one year, the total sum of positive effect on quality
of children’s life was 149,8%; health index 0,985 and
expenses on drug—3672,3 ± 40,4 roubles. Using 
sodium cromoglycate these indices were 70,9%; 0,965
and 1862,4 ± 24,2 roubles accordingly. Annual cost of
middle severe asthma for one child was 5051,4 ± 68,6
roubles using sodium nedocromil (72,7% expenditures
formed expenses on the drug); using sodium cromogly-
cate—5044,7 ± 110,4 roubles (36,92%) accordingly. In
the second case expenses on QALY were much more—
5207,65 in consequence of expenses on hospital care and
additional therapy.
CONCLUSIONS: Therapy by sodium cromoglycate of
middle severe asthma didn’t provide complete disease
control. In this case necessity in additional therapy for
improvement quality of life is increased.
PAR12
ESTIMATES OF THE COST OF ASTHMA IN A
EMPLOYER POPULATION
Atherly AJ1,Williams SG2
1Emory University / Centers for Disease Control, Atlanta, GA,
USA; 2Centers for Disease Control, Atlanta, GA, USA
